home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap


UBBFriend: Email This Page to Someone!
  HUM-MOLGEN
  Biotechnical requests and sources
  New Anti-CARMA Antibody Series Released by AnaSpec

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   New Anti-CARMA Antibody Series Released by AnaSpec
anaspec
Member
posted 06-17-2008 07:25 PM     Click Here to See the Profile for anaspec   Click Here to Email anaspec     Edit/Delete Message Reply w/Quote
San Jose, CA Jun 17, 2008
AnaSpec has introduced a new series of IHC validated antibodies, Anti-CARMA/CARD/Bimp antibodies.
CARMA proteins are scaffold molecules that belong to the membrane-associated guanylate kinase-like (MAGUK) and the caspase-associated recruitment domain (CARD) protein families. They play critical role in antigen receptor signaling pathways.1-4 CARMA-1 (CARD-11) CARMA-2 (CARD-14), and CARMA-3 (CARD-10) share homologous sequence and functions but are found in different tissues. CARMA1 is predominantly located in lymphoid tissue.5 CARMA-1 protein associates with lipid rafts1 and interacts with Bcl10, that is required for activation of TCR induced NFkB signaling pathway.1,2,4 Specifically, CARMA-1 N-terminal CARD domain binds to Bcl10 CARD motif.5 It is also essential for protein-induced IL-2 and INF- production.2 CARMA-2 is mostly found in placenta.5 CARMA-2 protein induces NFB activation; however, its signaling pathway it is not yet known.5 CARMA-3 is most abundant in nonhematopoietic cells.5 CARMA-3 protein physically associates with IKK complex and induces NFB activation via LPA signaling pathway.7 CARMA genes deactivation studies in mice resulted in reduced immunoglobulin levels and absence of TCR-induced NFB activation.4,6,7 This suggests that CARMA mutations may lead to adaptive and innate immunity malfunction.
Immunohistochemistry of these antibodies was performed by an anatomic pathologist on formalin-fixed, paraffin-embedded human or mouse tissues. Table 1 summarizes the IHC results. At least 22 different human or mouse tissues or cell types, including positive and negative tissues were used for each antibody tested. Dilutions of the antibodies at 2.5, 5, 10 and 20 ug/ml were tested, with the optimal concentration found to be at 10 ug/ml. These antibodies, provided at 50 ug, are sufficient for at least 5 IHCs. Moderate to strong staining with minimal background staining at the expected target tissues were observed for the antibodies. A representative image from a positively stained tissue is shown for each antibody. It shows the localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain.
Anti-CARMA Antibodies:
Anti-CARMA-1/CARD-11, human, Cat# 54982
Anti-CARMA-1/CARD-11, mouse, Cat# 54985
Anti-CARMA-2/CARD-14,human, Cat# 54983
Anti-CARMA-3/CARD-10,human, Cat# 54984
Anti-CARMA-3/CARD-10, mouse, Cat# 54987

Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry.
For more information, visit www.anaspec.com

REFERENCES
1. Gaide, O et al. Nat. Immunology 3: 836 (2002).
2. Hara, H. et al. JEM, 200, 1167 (2004).
3. Narayan, P. et al. Mol Cell Bio 26, 2327 (2006).
4. Egawa T. et al. Current Biology 13, 1252 (2003).
5. Grabiner, B. et al. Genes and Dev. 21, 984 (2007).
6. Newton, K. et al. Current Biology 13, 1247 (2003).
7. Stilo R. et al. J. Biol. Chem.279: 34323 (2004).

IP: 68.120.108.218

All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2015

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.